Background: Invasive pulmonary aspergillosis (IPA) remains a life-threatening condition despite systemic antifungal therapy. Objectives: This retrospective analysis investigated whether additional bronchoscopic instillation of amphotericin B (amB) would improve efficacy of antifungal treatment in patients with haematological malignancies suffering from IPA. Methods: Twenty patients (40.6 ± 14.2 years, 14 male) with preceding chemotherapy, bone marrow or stem cell transplantation complicated by severe IPA who did not respond sufficiently to systemic antifungal therapy were additionally treated by repeated bronchoscopic instillations of amB solution (91 instillations, on average 4.6 ± 2.2 instillations per patient over a period of 24.1 ± 21.0 days). Therapeutic response to this combined treatment regimen was monitored by chest X-ray and CT scan. Results: The mean infiltration sizes during systemic antifungal therapy alone (mean duration 11.9 ± 9.9 days) did not change significantly. However, after additional bronchoscopic instillation of amB solution infiltration sizes were reduced significantly (p < 0.05). A total resolution of infiltrates was seen in 3 and a partial reduction in 13 of 20 patients. Mean duration of total antifungal treatment was 50.1 ± 24.0 days. The mean follow-up period was 34.1 ± 31.2 months. The IPA-related mortality rate was 18.8% (3 of 16 patients). Conclusions: Additional bronchoscopic instillation of amB may improve the efficacy of systemic antifungal therapy in patients with haematological malignancies complicated by severe IPA. Bronchoscopic instillation of amB should be considered as an additional treatment option in cases with IPA unresponsive to systemic therapy.

Keywords:
Haematological malignancy, Pulmonary aspergillosis, Bronchoscopic therapy
1.
Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG, Stevens DA, Graybill JR: Invasive aspergillosis – disease spectrum, treatment practices and outcomes. Medicine (Baltimore) 2000;79:250–260.
2.
Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ, Patterson TF, Pankey GA: Practice guidelines for diseases caused by Aspergillus – Infectious Diseases Society of America. Clin Infect Dis 2000;30:696–709.
3.
Denning DW: Invasive aspergillosis. Clin Infect Dis 1998;26:781–803.
4.
Sharma OP, Chwogule R: Many faces of pulmonary aspergillosis. Eur Respir J 1998;12:705–715.
5.
Hoheisel G, Lange S, Winkler J, Rodloff AC, Liebert UG, Niederwieser D, Schauer J, Engelmann L: Nosocomial pneumonias in haematological malignancies in the medical intensive care unit. Pneumologie 2003;57:73–77.
6.
Piérard GE, Arrese JE, Quatresooz P: Comparative clinicopathological manifestations of human aspergillosis. Exog Dermatol 2004;3:144–153.
7.
Link H, Böhme A, Cornelli OA, Höffken K, Kellner O, Kern WV, Mahlberg R, Maschmeyer G, Nowrousian MR, Ostermann H, Ruhnke M, Sezer O, Schiel X, Wilhelm N, Auner HW: Antimicrobial therapy of unexplained fever in neutropenic patients – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology. Ann Hematol 2003;82:S105–S117.
8.
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–415.
9.
Polak A: The past, present and future of antimycotic combination therapy. Mycoses 1999;42:355–370.
10.
Denning DW: Diagnosis and management of invasive aspergillosis. Curr Clin Top Infect Dis 1996;16:277–299.
11.
Denning DW, Evans EGV, Kibbler CC, Richardson MD, Roberts MM, Rogers TR, Warnock DW, Warren RE: Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. Eur J Microbiol Infect Dis 1997;16:424–436.
12.
Krcmery VC Jr: Antifungal chemotherapeutics. Med Princ Pract 2005;14:125–135.
13.
Caillot D: Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol 2003;109:111–118.
14.
Gurwith M: Clinical efficacy of amphotericin B colloidal dispersion against infections caused by Aspergillus spp. Chemotherapy 1999;45:34–38.
15.
Buchheidt D, Spiess B, Hehlmann R: Systemic infections with Aspergillus species in patients with hematological malignancies: current serological and molecular diagnostic approaches. Onkologie 2001;24:531–536.
16.
Lass-Flörl C, Kofler G, Kropshofer G, Hermans J, Kreczy A, Dierich MP, Niederwieser D: In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998;42:497–502.
17.
Bolliger CT, Sutedja TG, Stausz J, Freitag L: Therapeutic bronchoscopy with immediate effect: laser, electrocautery, argon plasma coagulation and stents. Eur Respir J 2006;27:1258–1271.
18.
Ramirez RJ: Pulmonary aspergilloma – endobronchial treatment. N Engl J Med 1964;271:1281–1285.
19.
Guleria R, Gupta D, Jindal SK: Treatment of pulmonary aspergilloma by endoscopic intracavitary instillation of ketoconazole. Chest 1993;103:1301–1302.
20.
Itoh T, Yamada H, Yamaguchi A, Kawamata N, Kakei M, Nozoe S, Tanaka H: Percutaneous intracavitary antifungals for a patient with pulmonary aspergilloma; with a special reference to in vivo efficacies and in vitro susceptibility results. Intern Med 1995;34:85–88.
21.
Giron J, Poey C, Fajadet P, Sans N, Fourcade D, Senac JP, Railhac JJ: CT-guided percutaneous treatment of inoperable pulmonary aspergillomas: a study of 40 cases. Eur J Radiol 1998;28:235–242.
22.
Hargis JL, Bone RC, Stewart J, Rector N, Hiller FC: Intracavitary amphotericin B in the treatment of symptomatic pulmonary aspergillomas. Am J Med 1980;68:389–394.
23.
Veltri A, Anselmetti GC, Bartoli G, Martina MC, Regge D, Galli J: Percutaneous treatment with amphotericin B of mycotic lung lesions from invasive aspergillosis: results in 10 immunocompromised patients. Eur Radiol 2000;10:1939–1944.
24.
Harashima S, Tsukamoto H, Nishizaka H, Otsuka J, Horiuchi T: Successful treatment of invasive pulmonary aspergillosis by transbronchial injection of urinary trypsin inhibitor and amphotericin B. Acta Haematol 2003;109:156–157.
25.
Nakase K, Yazaki A, Tamaki S, Tanigawa M, Tsuji K, Miyanishi E, Shiku H: Effect of direct infusion of antifungal agent on invasive pulmonary aspergillosis in a patient with acute leukemia. J Infect Chemother 2002;8:106–108.
26.
Reichenberger F, Habicht JM, Gratwohl A, Tamm M: Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J 2002;19:743–755.
27.
Dohen-Bécue F, Salez F, Ramon P, Leblond-Tillie I, Wallaert B, Bauters A, Tonnel AB: Management of hemoptysis in invasive pulmonary aspergillosis. Rev Mal Respir 1998;15:791–796.
28.
Böhme A, Karthaus M, Hoelzer D: Antifungal prophylaxis in neutropenic patients with hematologic malignancies: is there a real benefit? Chemotherapy 1999;45:224–232.
29.
Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7–14.
30.
Curtis AM, Smith GJ, Ravin CE: Air crescent sign of invasive aspergillosis. Radiology 1979;133:17–21.
31.
Denning DW: Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608–615.
32.
Denning DW, Evans EGV, Kibbler CC, Richardson MD, Roberts MM, Rogers TR, Warnock DW, Warren RE: Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. Eur J Microbiol Infect Dis 1997;16:424–436.
33.
Bennett MR, Weinbaum DL, Fiehler PC: Chronic necrotizing pulmonary aspergillosis treated by endobronchial amphotericin B. South Med J 1990;83:829–832.
34.
Scholer HJ: Chemotherapie der Aspergillenkrankheiten der Lunge. Mykosen 1983;26:173–196.
35.
Brown MJ, Worthy SA, Flint JDA, Müller NL: Invasive aspergillosis in the immunocompromised host: utility of computed tomography and bronchoalveolar lavage. Clin Radiol 1998;53:255–257.
36.
Lee KS, Kim HT, Kim YH, Choe KO: Treatment of hemoptysis in patients with cavitary aspergilloma of the lung: value of percutaneous instillation of amphotericin B. Am J Roentgenol 1993;161:727–731.
37.
Hargis JL, Bone RC, Stewart J, Rector N, Hiller FC: Intracavitary amphotericin B in the treatment of symptomatic pulmonary aspergillomas. Am J Med 1980;68:389–394.
38.
Barnes AJ, Oppenheim BA, Chang J, Morgenstern GR, Scarffe JH: Early investigation and initiation of therapy for invasive pulmonary aspergillosis in leukaemic and bone marrow transplant patients. Mycoses 1999;42:403–408.
39.
Diederich S, Scadeng M, Dennis C, Stewart S, Flower CDR: Aspergillus infection of the respiratory tract after lung transplantation: chest radiographic and CT findings. Eur Radiol 1998;8:306–312.
40.
Seyfarth HJ, Nenoff P, Winkler J, Krahl R, Klöppel R, Wirtz H, Borte G: Invasive Pulmonale Aspergillose – CT-Befunde im Kontext des klinischen Verlaufes. Rofo 2002;174:1115–1120.
41.
Schuster F, Moelter C, Schmid I, Graubner UB, Kammer B, Belohradsky BH, Fuhrer M: Successful antifungal combination therapy with voriconazole and caspofungin. Pediatr Blood Cancer 2005;44:682–685.
42.
Groll AH, Walsh TJ: Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther 2005;3:467–487.
43.
Bennett JE, Kauffman C, Walsh T, de Pauw B, Dismukes W, Galgiani J, Glauser M, Herbrecht R, Lee J, Pappas P, Powers J, Rex J, Verweij P, Viscoli C: Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups. Clin Infect Dis 2003;36(suppl 3):123–127.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.